drug results showed increased risk nonserious adverse effects medical cannabis group difference risk adverse events studies specifically examine cannabis substitute opioids providing pain relief limited patients largest observational study underway tilray canadian producer cannabis products backed 1,000 patient study extends 20 canadian clinics covers total months research relied patient self reporting great useful says philippe lucas vice president patient advocacy tilray need study substitution effect real time experimental clinical trials provide definitive proof cause effect relation medical cannabis reduced opioid use says mark ware director clinical research alan edwards pain management unit mcgill university lead author safety study experimental research